Talphera, Inc. TLPH
Talphera, Inc. (Nasdaq: TLPH) is a cardio-renal-metabolic drug developer. Its lead program, Niyad, is in Phase 3 for regional anticoagulant for the dialysis circuit (CRRT). Its next catalyst on record is Niyad: enrollment completion (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Niyad — enrollment completion (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Niyad | regional anticoagulant for the dialysis circuit (CRRT) | small molecule | Phase 3 |
| LTX-608 | disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), acute pancreatitis, or anti-viral treatment | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.